ASTRO 2025: A Randomized, Parallel Phase II Trial of Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer with Pelvic and/or Para-aortic Lymph Node Involvement Following Primary Localized Treatment with Radiotherapy – UroToday

1. ASTRO 2025: A Randomized, Parallel Phase II Trial of Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer with Pelvic and/or Para-aortic Lymph Node Involvement Following Primary Localized Treatment with Radiotherapy  UroToday
2. Combining radiopharmaceuticals with targeted radiation improves progression-free survival in prostate cancer patients  News-Medical
3. Adding PSMA-targeting radioligand therapy to stereotactic body radiotherapy more than doubled progression-free survival in men with recurrent prostate cancer  UCLA Health
4. ASTRO: Targeted Radioactive Therapy, New SBRT Approaches, 5DCT-Guided Imaging and More  Oncodaily
5. Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate Cancer  CancerNetwork

Continue Reading